Stroke Trials Registry

Enlimomab
Anti-ICAM-1 antibody

Action
Monoclonal antibody against intercellular adhesion molecule ICAM-1; ICAM is required for leukocyte attachment and migration through cerebral endothelium.

Status
Phase III trial (EAST) enrolment of 625 patients was completed in July 1996 and the results presented in April 1997. Outcome in Enlimomab group worse than placebo group. Final results published 10/2001.

Trial(s)
= Ongoing
= Completed

EAST Enlimomab Acute Stroke Trial

Web Links and Publications

Boehringer Ingelheim Web Site.

Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial.
Neurology 2001 Oct 23;57(8):1428-34.

Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): an open-label, dose escalation study in patients hospitalized for acute stroke.
Eur Neurol. 1998 Aug;40(2):78-83.

UID: 18